A PYMNTS Company

US: Pfizer inks new partnership after AstraZeneca failure

By  |  June 18, 2014

Following US pharmaceutical giant Pfizer’s failed attempt to acquire AstraZeneca, reports say Pfizer has inked a new joint venture deal to develop immunotherapy cancer drugs.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    According to reports, Pfizer will team up with France-based Cellectis. The partnership involves Pfizer paying Cellectis $80 million upfront, as well as funding for ongoing research into the new treatment.

    Among the other aspects of the deal, Pfizer will also acquire a 10 percent stake in the French company.

    The joint venture was announced Wednesday and follows last month’s failure for Pfizer to convince AstraZeneca to merge. Pfizer raised its bid as high as $118 billion to purchase the UK firm.

    Full content: Yahoo News

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.